ANTIPHOSPHOLIPID ANTIBODIES AND PREGNANCY LOSS

被引：29

作者：

OUT, HJ

BRUINSE, HW

DERKSEN, RHWM

机构：

[1] Department of Internal Medicine, Division of Immunopathology

[2] Department of Obstetrics and Gynaecology, University Hospital Utrecht, 3508 GA Utrecht

来源：

HUMAN REPRODUCTION | 1991年 / 6卷 / 06期

关键词：

ABORTION; ANTICARDIOLIPIN ANTIBODIES; ANTIPHOSPHOLIPID ANTIBODY; LUPUS ANTICOAGULANT; PREGNANCY;

D O I：

10.1093/oxfordjournals.humrep.a137446

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Anti-phospholipid antibodies such as the lupus anticoagulant and anti-cardiolipin antibodies, are antibodies directed at negatively charged phospholipids and have received much attention in the last decade. Their presence has been associated with a thrombotic tendency, leading to a variety of clinical symptoms. In the pregnant woman, the presence of these antibodies may have consequences for management, since retrospective reports have established a correlation between the lupus anticoagulant or anti-cardiolipin antibodies with intrauterine fetal death, probably due to placental thrombosis. This article reviews current knowledge on anti-phospholipid antibodies in relation to pregnancy loss, focusing on clinical aspects.

引用

页码：889 / 897

页数：9

共 107 条

[21]

Cowchock S., Smith B., Gocial B., Antibodies to phospholipids and nuclear antigens in patients with repeated abortions, Am. J. Obstet. Gynecol, 155, pp. 1002-1010, (1986)

[22]

Derksen R.H.W.M., Kater L., Lupus anticoagulant: Revival of an old phenomenon, Clin. Exp. Rheumatol, 3, pp. 349-357, (1985)

[23]

Derksen R.H.W.M., Bouma B.N., Kater L., The striking association between lupus anticoagulant and fetal loss in systemic lupus erythematosus patients, Arthritis Rheum, 29, pp. 695-696, (1986)

[24]

Derksen R.H.W.M., Biesma D., Bouma B.N., Gmelig Meyling F.H.J., Kater L., Discordant effects of prednisone on anti-cardiolipin antibodies and the lupus anticoagulant, Arthritis Rheum, 29, pp. 1295-1296, (1986)

[25]

Derksen R.H.W.M., Hasselaar P., Blokzijl L., Gmelig Meyling F.H.J., Groot D., Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients, Ann. Rheum. Dis, 47, pp. 364-371, (1988)

[26]

Derksen R.H.W.M., Out H.J., Bruinse H.W., Christiaens G.C.M.L., Van Vliet M., Groot P.G., Drug Treatment in Pregnant Women with Anti-Phospholipid Antibodies. a Preliminary Report of a Prospective Study (Abstract). Clin. Exp. Rheumatol, 8, (1990)

[27]

Derue G.J., Englert H.J., Harris E.N., Gharavi A.E., Morgan S.H., Hull R.G., Elder M.G., Hawkins D.F., Hughes G.R.V., Fetal loss in systemic lupus: Association with anticardiolipin antibodies, J. Obstet. Gynaecol, 5, pp. 207-209, (1985)

[28]

Druzin M.L., Lockshin M.D., Edersheim T.G., Hutson J.M., Krauss A.L., Kogut E., Second-trimester fetal monitoring and preterm delivery in pregnancies with systemic lupus erythematosus and/or circulating anticoagulant, Am. J. Obstet. Gynecol, 157, pp. 1503-1510, (1987)

[29]

Dudley D.J., Mitchell M.D., Branch D.W., Pathophysiology of antiphospholipid antibodies: Absence of prostaglandin-mediated effects on cultured endothelium, Am. J. Obstet. Gynecol, 162, pp. 953-959, (1990)

[30]

Edelman P., Rouquette A.M., Verdy E., Elias A., Cabane J., Comet D., Barrat J., Chavinie J., Salat-Baroux J., Sureau C., Autoimmunity, fetal losses, lupus anticoagulant: Beginning of systemic lupus erythematosus or new autoimmune entity with gynaeco-obstetrical expression?, Hum. Reprod, 1, pp. 295-297

← 1 2 3 4 5 6 7 8 9 10 →